Bausch & Lomb

Pharmatech Associates Adds Biotech Leader Praveen Tyle, Ph.D. to Board of Trustees

Retrieved on:

Martedì, Gennaio 16, 2024

Other Health, Professional Services, Pharmaceutical, Oncology, Other Manufacturing, Clinical Trials, Science, Biotechnology, FDA, Health, Consulting, Other Science, Manufacturing, Bausch & Lomb, Trustee, USP, Lexicon Pharmaceuticals

Pharmatech Associates, a subsidiary of the United States Pharmacopeia (USP), today announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees.

Key Points:

Pharmatech Associates, a subsidiary of the United States Pharmacopeia (USP), today announced it has appointed the biotech expert Dr. Praveen Tyle to its board of trustees.
“As we focus on providing expert consulting services to an array of biotechnology clients, Dr. Tyle’s incomparable experience and valuable market insight will inform the Pharmatech Associates board,” said Emily Kaine, Pharmatech Associates’ board chair.
“Dr.
“Backed by USP’s sustained investment and global network, Pharmatech has a promising, ambitious long-term global growth trajectory as it helps drug manufacturers meet international regulatory requirements and their own business objectives.”

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on:

Lunedì, Gennaio 8, 2024

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points:

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
“FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Lunedì, Novembre 13, 2023

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points:

ET -
ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Retrieved on:

Mercoledì, Novembre 15, 2023

Recycling, Medical Supplies, Health, Environment, Sustainability, Optical, Bausch, NYSE, Patient, Dependent and independent variables, Bausch & Lomb, Contact, Food, Contact lens, Safety, Telescopic sight

Contact lenses, eye care and lens care materials aren’t typically processed in standard recycling facilities due to the small size and the type of plastic used to manufacture them.

Key Points:

Contact lenses, eye care and lens care materials aren’t typically processed in standard recycling facilities due to the small size and the type of plastic used to manufacture them.
“My patients appreciate being able to recycle their used eye health materials through the Bausch + Lomb recycling programs in an environmentally responsible way,” said Jennifer Tsai, O.D., LINE OF SIGHT, New York.
In addition to the United States, Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.
To learn more about the Biotrue Eye Care Recycling program, visit https://www.biotrue.com/terracycle/ .

Magnit Welcomes Efrain Rivera to Its Board of Directors

Retrieved on:

Mercoledì, Novembre 15, 2023

Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, IWM, Growth, Paychex, Bausch, Knowledge, Bausch & Lomb, Management, Magnit

Magnit, an Integrated Workforce Management (IWM) platform provider, is pleased to announce that Efrain Rivera will join its Board of Directors.

Key Points:

Magnit, an Integrated Workforce Management (IWM) platform provider, is pleased to announce that Efrain Rivera will join its Board of Directors.
“We are thrilled to welcome Efrain Rivera to our Board of Directors,” said Teresa Carroll, CEO of Magnit.
“Efrain Rivera’s remarkable achievements and strategic acumen align perfectly with our company’s mission and values,” added Mason Slaine, Chairman of Magnit’s Board.
“I am honored to join the Board of such an established leader in contingent workforce management,” Rivera said of his appointment.

Toshiba Global Commerce Solutions Appoints Todd Regelsberger as Chief Financial Officer

Retrieved on:

Martedì, Novembre 14, 2023

Toshiba Global Commerce Solutions announced that Todd Regelsberger joined the company as its new Chief Financial Officer (CFO), effective November 6, 2023.

Key Points:

Toshiba Global Commerce Solutions announced that Todd Regelsberger joined the company as its new Chief Financial Officer (CFO), effective November 6, 2023.
Regelsberger comes to Toshiba with more than 25 years of financial experience leading financial teams across controllership, internal auditing, treasury, financial planning and analysis, manufacturing, and international operations.
View the full release here: https://www.businesswire.com/news/home/20231114483428/en/
Todd Regelsberger joins Toshiba Global Commerce Solutions as CFO and brings over 25 years of experience leading financial teams across multiple high-profile organizations worldwide.
His extensive history with international organizations and leadership will contribute to Toshiba Global Commerce Solutions' continued growth as a global leader in retail technology.

KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implants

Retrieved on:

Lunedì, Novembre 13, 2023

Biotechnology, Optical, Health, Medical Devices, Eye, Vision, Johnson & Johnson, Organization, Food, Alcon, Infection, Opacity (optics), PEN, Bausch & Lomb, KLI, PV, Cryptocurrency, Developing country

Pantheon Vision, an early-stage ophthalmic medical device company KLI established, will use the funding to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs.

Key Points:

Pantheon Vision, an early-stage ophthalmic medical device company KLI established, will use the funding to develop bioengineered corneal implants to reduce reliance on donated corneal tissue – often unavailable in LMICs.
“Development of novel therapeutic solutions is costly but critical to fulfilling our mission of eradicating corneal blindness,” said Douglas J. Furlong, KLI Board Chairman.
More than 12.7 million children and adults are blind because of corneal injuries or infections, and millions more are blind in one eye or live with seriously impaired vision.
KLI is rewriting the narrative of corneal health by advancing ground-breaking products, technologies, and services to eradicate corneal blindness with specific emphasis on low- and middle-income countries.

Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implant

Retrieved on:

Giovedì, Novembre 2, 2023

Bausch & Lomb, FDA, Food, KLI, Organization, Hoya, Developing country, Alcon, Johnson & Johnson, Patient, Opacity (optics), Management, Pharmaceutical industry

BALTIMORE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pantheon Vision, an early-stage ophthalmic medical device company, has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI).

Key Points:

BALTIMORE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pantheon Vision, an early-stage ophthalmic medical device company, has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI).
"We are thrilled to have KeraLink provide our initial funding to establish Pantheon Vision as a company dedicated to bringing groundbreaking ophthalmic innovations to patients worldwide,” expressed John Sheets, Ph.D., Chief Executive Officer of Pantheon Vision.
“This funding enables us to advance our program to eradicate corneal blindness and restore vision.”
Pantheon Vision is creating bioengineered implants to raise the standard of eye care globally and reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries (LMICs).
The company will engage the U.S. Food and Drug Administration (FDA) in the coming months to guide plans for global product development.

MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer

Retrieved on:

Mercoledì, Novembre 1, 2023

Therapy, Biotechnology, Human resources, MBX, Parexel, Growth, Bausch, Michigan State University, Business administration, Bristol Myers Squibb, GSK, Culture, Ipsen, Bausch & Lomb, Management, Patient

CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer.

Key Points:

CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Michelle Graham as Chief Human Resources Officer.
Ms. Graham is a seasoned global executive with 25+ years of experience leading human resources across a broad range of companies in the biopharmaceutical and healthcare industries.
“Michelle is an exceptionally experienced human resources executive with an impressive track record of leading global teams, developing and executing HR strategies, and fostering a diverse and inclusive culture,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
“I am pleased to join the impressive MBX Biosciences team at this pivotal time in the company’s trajectory,” said Ms. Graham.

Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones

Retrieved on:

Venerdì, Ottobre 20, 2023

Mont Blanc, Intraocular pressure, Ocular hypertension, IOP, Nitric oxide, Acquisition, Glaucoma, NCX, Euronext Paris, Marshal of France, COVID-19, Whistler, Bausch & Lomb, Patient, ZTF J1813+4251, Music, Pharmaceutical industry, Cryptocurrency

Cash of €14.6 million on September 30, 2023

Key Points:

Cash of €14.6 million on September 30, 2023
Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial results for Nicox SA and its subsidiaries (the “Nicox Group”) for the first half of 2023 and for the third quarter of 2023 and provided an update on key future milestones.
Operating expenses for the first half of 2023 were €10.4 million compared to €12.7 million for the first half of 2022.
Net revenue for the third quarter of 2023 was €1.1 million (entirely composed of net royalty payments).
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 22% in the third quarter of 2023 compared to the same period in 2022.